Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 8.4% – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) traded down 8.4% on Thursday . The company traded as low as $23.50 and last traded at $23.0150. 2,582 shares were traded during mid-day trading, a decline of 17% from the average session volume of 3,113 shares. The stock had previously closed at $25.13.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. Based on data from MarketBeat, Ascentage Pharma Group International presently has an average rating of “Buy” and a consensus price target of $48.00.

Ascentage Pharma Group International Price Performance

The company has a 50-day simple moving average of $24.45 and a 200-day simple moving average of $28.20. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million during the quarter. As a group, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International during the third quarter valued at $96,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International during the third quarter worth about $204,000. Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, XY Capital Ltd raised its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.